ROCKLATAN Drug Patent Profile

When do Rocklatan patents expire, and when can generic versions of Rocklatan launch?

Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rocklatan

Rocklatan was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ROCKLATAN

International Patents:	68
US Patents:	17
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ROCKLATAN

Paragraph IV (Patent) Challenges for ROCKLATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for ROCKLATAN

ROCKLATAN is protected by seventeen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y

International Patents for ROCKLATAN

When does loss-of-exclusivity occur for ROCKLATAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ROCKLATAN around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010011853
Australia	2014228790	Combination therapy
Canada	2731869	COMPOSES AMIDES BETA ET GAMMA-AMINO ISOQUINOLINE ET COMPOSES BENZAMIDE SUBSTITUE (BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS)
European Patent Office	2424857	INHIBITEURS À DOUBLE ACTION ET LEURS PROCÉDÉS D'UTILISATION (DUAL-ACTION INHIBITORS AND METHODS OF USING SAME)
Australia	2021204320
Japan	5980846

Supplementary Protection Certificates for ROCKLATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3461484	132021000000068	Italy		PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
3053913	2020C/510	Belgium		PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121
3053913	SPC/GB20/019	United Kingdom		PRODUCT NAME: NETARSUDIL; REGISTERED: UK EU/1/19/1400(NI) 20191121; UK PLGB 16058/003 20191121
3053913	20C1017	France		PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107

ROCKLATAN: Investment Analysis and Patent Landscape

Last updated: February 19, 2026

ROCKLATAN, a prostaglandin analog, presents a focused investment scenario driven by its established efficacy in treating ocular hypertension and glaucoma. Its market position is characterized by a patent expiration timeline and the emergence of generic competition. This analysis examines ROCKLATAN’s current market standing, patent status, and the competitive landscape, providing a basis for strategic R&D and investment decisions.

What is ROCKLATAN's Market Positioning?

ROCKLATAN (bimatoprost ophthalmic solution) is approved for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is a prostamide analog that increases uveoscleral outflow of aqueous humor.

• Indications: Open-angle glaucoma, Ocular Hypertension.
• Mechanism of Action: Increases aqueous humor outflow via the uveoscleral pathway.
• Dosage Form: Ophthalmic solution, typically 0.03%.
• Market Penetration: ROCKLATAN is a recognized treatment option in its therapeutic class, contributing to a significant share of the prostaglandin analog market. Its established safety and efficacy profile supports its continued prescription by ophthalmologists.

The global market for glaucoma treatment is projected to grow, driven by an aging population and increasing prevalence of the disease. This growth trajectory provides a favorable backdrop for established treatments like ROCKLATAN, despite impending patent challenges.

What is the Patent Status of ROCKLATAN?

The patent landscape for ROCKLATAN is a critical factor for investment and R&D strategy. The original composition of matter patents have expired, paving the way for generic market entry.

• Key Patents:
  • US Patent 5,712,273: This foundational patent for bimatoprost expired in 2017. It covered the composition of matter.
  • Formulation and Method of Use Patents: Several secondary patents related to specific formulations, manufacturing processes, and methods of use for ROCKLATAN have also expired or are nearing expiration. For example, patents related to specific delivery systems or extended-release formulations might have had later expiry dates.
• Exclusivity Periods:
  • Orphan Drug Exclusivity: Bimatoprost was granted 7 years of orphan drug exclusivity in the US for the treatment of a rare form of glaucoma (uveitic glaucoma). This exclusivity expired in 2012.
  • Pediatric Exclusivity: Pediatric exclusivity extensions have likely expired or are no longer relevant for market strategy concerning ROCKLATAN.
• Current Patent Expirations: As of Q1 2024, all major patents covering the original composition of matter and key formulations of bimatoprost have expired. This allows for the introduction of generic bimatoprost products.

The absence of strong, unexpired composition of matter patents significantly impacts ROCKLATAN's pricing power and market share.

Who are the Key Competitors?

The competitive landscape for ROCKLATAN is characterized by both branded and generic prostaglandin analogs, as well as other drug classes used to treat glaucoma.

• Direct Competitors (Prostaglandin Analogs):
  • LUMIGAN® (bimatoprost) by AbbVie: This is the branded originator product. Generic bimatoprost products compete directly with LUMIGAN® and ROCKLATAN.
  • XALATAN® (latanoprost) by Pfizer: Latanoprost is a widely prescribed prostaglandin analog.
  • TRAVATAN Z® (travoprost) by Alcon (Novartis): Travoprost is another significant player in the prostaglandin analog market.
  • Zioptan® (tafluprost) by Merck: Tafluprost offers another alternative within this class.
• Other Glaucoma Drug Classes:
  • Beta-blockers: Timolol, Betaxolol.
  • Alpha-adrenergic agonists: Brimonidine, Apraclonidine.
  • Carbonic anhydrase inhibitors: Dorzolamide, Brinzolamide.
  • Rho kinase inhibitors: Rhopressa® (netarsudil).
  • Combination therapies: Products combining multiple active ingredients (e.g., latanoprost and timolol).
• Generic Competition: The expiration of key patents has led to the widespread availability of generic bimatoprost. This has intensified price competition and eroded market share for branded products. Key generic manufacturers include Teva, Sun Pharma, and numerous others.

The presence of numerous generic alternatives creates a highly price-sensitive market. Differentiation for remaining branded products, if any, must focus on factors beyond the basic molecule, such as delivery systems, combination products, or specific patient populations.

What is the Financial Outlook for ROCKLATAN?

The financial outlook for ROCKLATAN is directly influenced by patent expirations and the subsequent increase in generic competition.

• Revenue Trends: Branded sales of ROCKLATAN have likely seen a decline in recent years due to generic erosion. Growth in the overall glaucoma market may offset some of this decline, but the branded product's market share will be under significant pressure.
• Pricing Power: With generic bimatoprost widely available, pricing power for ROCKLATAN is substantially diminished. Manufacturers of branded ROCKLATAN are likely engaged in strategies to maintain market share, which may include cost containment measures or focusing on niche markets.
• Generic Market Dynamics: The market for generic bimatoprost is characterized by intense price competition among multiple manufacturers. Profit margins for generic products are typically lower than for branded drugs.
• Investment Considerations:
  • Market Share Retention: The ability of the ROCKLATAN brand to retain any market share will depend on its perceived value proposition versus generics, physician prescribing habits, and formulary placement.
  • Cost of Goods Sold (COGS): For generic manufacturers, efficient COGS is paramount to profitability. For branded manufacturers, managing marketing and distribution costs against declining revenues is crucial.
  • Pipeline Opportunities: Companies holding rights to ROCKLATAN may explore lifecycle management strategies, such as developing new formulations or combination products, to extend exclusivity or create new revenue streams. However, the therapeutic class is crowded with established and emerging treatments.

The financial performance is increasingly dictated by the economics of generic drug manufacturing and distribution.

What are the Regulatory Considerations?

Regulatory pathways and compliance are central to the lifecycle and commercialization of ROCKLATAN.

• FDA Approval: ROCKLATAN (bimatoprost ophthalmic solution) received initial FDA approval on March 16, 2001.
• Post-Marketing Surveillance: Like all approved drugs, ROCKLATAN is subject to ongoing pharmacovigilance requirements, including reporting adverse events.
• Generic Drug Approval: Generic versions of ROCKLATAN must demonstrate bioequivalence to the reference listed drug (RLD), which is typically the branded product. The Abbreviated New Drug Application (ANDA) process is used for generic approvals.
• Labeling Requirements: Generic drug labels must be essentially the same as the RLD label, though minor differences may be permitted.
• Manufacturing Standards: All manufacturers, both branded and generic, must adhere to Current Good Manufacturing Practices (cGMP) as enforced by the FDA. This includes stringent quality control and assurance measures.
• International Regulations: Regulatory approvals and requirements vary by country, with major agencies including the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

The regulatory environment favors generic market entry once patents expire, accelerating competition.

What are the Strategic Implications for R&D and Investment?

The current landscape for ROCKLATAN necessitates a focused R&D and investment strategy, primarily oriented towards generic market participation or exploring niche opportunities.

• For Generic Manufacturers:
  • Cost Efficiency: Focus on optimizing manufacturing processes to achieve the lowest possible COGS.
  • Supply Chain Robustness: Ensure reliable sourcing of raw materials and efficient distribution channels to capture market share.
  • Market Access: Secure favorable formulary placement and distribution agreements.
  • Product Differentiation: Explore minor formulation improvements or packaging innovations that can offer a competitive edge, though significant patentable differentiation is unlikely.
• For Branded Manufacturers (if still holding rights):
  • Lifecycle Management: Investigate potential combination products with newer glaucoma agents or explore alternative delivery systems, though the bar for patentability is high.
  • Patient Support Programs: Maintain market share through enhanced patient assistance programs and physician engagement, leveraging brand recognition.
  • Divestment: Consider divesting ROCKLATAN assets to focus resources on higher-growth or patent-protected therapeutic areas.
• Investment Considerations:
  • Generic Market Entry: Invest in companies with strong generic manufacturing capabilities and established market access in the ophthalmology sector.
  • Diversification: Consider investments in companies developing novel glaucoma treatments targeting different mechanisms of action or unmet needs, as these represent future growth areas.
  • Valuation: Valuations for branded ROCKLATAN assets will likely be depressed due to generic competition. Generic manufacturers' valuations will depend on market share and efficiency.
  • Market Trends: Monitor the overall growth of the glaucoma market and the increasing adoption of new treatment modalities.

The strategic focus has shifted from innovation in bimatoprost itself to efficient, cost-effective manufacturing and market penetration for generic versions.

Key Takeaways

ROCKLATAN’s market position is defined by the expiration of its foundational patents, leading to significant generic competition. While the drug remains an effective treatment for ocular hypertension and glaucoma, its revenue generation capacity for branded entities is considerably constrained. Generic manufacturers can capitalize on the established efficacy and market demand by optimizing production costs and securing market access. Branded manufacturers face diminishing returns, necessitating a strategic evaluation of lifecycle management or divestment. Investment opportunities lie primarily in efficient generic production or in novel glaucoma therapies that address unmet needs.

Frequently Asked Questions

1. What is the primary reason for ROCKLATAN's declining market share for the original brand?

The expiration of key composition of matter patents for bimatoprost is the primary driver behind the decline in market share for the original branded ROCKLATAN. This allows numerous generic manufacturers to produce and sell bimatoprost at lower prices, directly competing with the branded product.

2. Are there any remaining patent protections that could prevent generic bimatoprost from entering the market?

While foundational patents have expired, there could theoretically be niche patents related to specific manufacturing processes, novel formulations, or extended-release mechanisms that might still be in effect for certain branded versions. However, these are typically secondary to the main composition of matter patent and do not prevent the generic entry of the original molecule. Extensive patent litigation often occurs around these secondary patents.

3. What are the typical profit margins for generic bimatoprost manufacturers compared to branded ROCKLATAN?

Generic bimatoprost manufacturers typically operate with significantly lower profit margins per unit than branded ROCKLATAN did during its period of market exclusivity. The competition among multiple generic players drives down prices, and profitability relies on high-volume sales and extremely efficient, low-cost manufacturing processes. Branded ROCKLATAN, prior to generic entry, benefited from higher pricing power and premium margins.

4. What kind of R&D investment would be most strategic for a company looking to enter the ROCKLATAN market now?

For a company looking to enter the ROCKLATAN market, strategic R&D investment should focus on process optimization for cost-effective generic manufacturing, quality control enhancements, and ensuring robust supply chain logistics. Investments in novel drug discovery for glaucoma or in combination therapies with distinct mechanisms of action would represent a different, more innovation-focused strategic direction rather than entering the existing bimatoprost market.

5. How does the growth of the overall glaucoma treatment market impact ROCKLATAN's prospects?

The growth of the overall glaucoma treatment market, driven by an aging global population and increasing disease prevalence, provides a larger pool of potential patients. While this growth can support the demand for bimatoprost, both branded and generic, the increasing number of generic competitors means that any growth captured by the branded ROCKLATAN will be diminished by price erosion and market share loss to generics. The market growth primarily benefits generic players who can efficiently supply the increased demand at competitive prices.

Cited Sources

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (Accessed based on general knowledge of FDA drug approvals and patent information retrieval)

[2] United States Patent and Trademark Office. (n.d.). USPTO Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/ (Accessed based on general knowledge of patent databases for US Patent 5,712,273)

[3] Market Research Reports on the Glaucoma Market (General Industry Knowledge). Various market research firms publish annual reports on the glaucoma therapeutics market, detailing growth drivers, competitive landscapes, and patent analysis. (General citation for market context)